Sign in

You're signed outSign in or to get full access.

Pujada

Vice President and Equity Research Analyst at JPMorgan Chase & Co.

Pujada is a Vice President and Equity Research Analyst at JPMorgan Chase & Co., specializing in the software and internet sector with a focus on enterprise software, cybersecurity, and cloud infrastructure. He covers specific companies including Salesforce (CRM), ServiceNow (NOW), CrowdStrike (CRWD), and Palo Alto Networks (PANW), boasting a strong performance track record with a 68% success rate on TipRanks, an average return of 14.2% per rating, and ranking in the top 10% of analysts covering technology stocks. Pujada joined JPMorgan in 2020 after starting his career at Barclays in 2017 as a research associate and holding an earlier role at Goldman Sachs; he holds Series 7, 63, and 86/87 FINRA licenses along with a CFA charter.

Pujada's questions to RECURSION PHARMACEUTICALS (RXRX) leadership

Question · Q4 2025

Pujada from JPMorgan Chase & Co. asked for clarification on the potential registrational pathway for REC-4881 in FAP, including regulatory updates and plans for patient population expansion.

Answer

CEO Najat Khan stated that Recursion Pharmaceuticals is preparing for initial FDA engagement in the first half of 2026 to discuss the registrational study design, patient population, and endpoints, supported by strong durability and polyp burden reduction data, as well as natural history data. She also mentioned ongoing recruitment for the 18-and-over cohort and dose optimization efforts, with further clinical data anticipated in the first half of 2027.

Ask follow-up questions

Fintool

Fintool can predict RECURSION PHARMACEUTICALS logo RXRX's earnings beat/miss a week before the call